Among these outstanding products is the CPAP Flow Generator for the production of 250 Ventipap Neuronic emergency ventilation equipment, Umelisa SARS-CoV-2 Antigen, and the Umelisa SARS-COV-2 Anti RBD, Niurka Carlos Pías, CIE Director, stated.
Regarding Umelisa SARS-COV-2 Igg and Umelisa Anti-SARS-CoV-2, both were used in the seroprevalence study, she added.
Plus, the CIE specialists are currently working on developing an RT PCR system for accurate detection of new coronavirus variants and a nucleic acid extractor, which will provide tech sovereignty to the national molecular biology lab networks.
In 2021, CIE went on conducting separate research projects closely related to the use of nanoparticles for new diagnostics, as well as products for neonatal screening and blood certification, rapid tests and tests for agricultural health, among others.
Since 2021, CIE managed to manufacture as many as 127,688 kits for 30 diagnostic systems, corresponding to over 46.2 million determinations, a figure nearly four million higher than that reached in 2020.
A dozen of these diagnostic systems produced more than a million determinations, the Granma newspaper reported.
Concerning the SUMA technology (Ultramicroanalytical System), it was used in 34 clinical trials and provided Cuba´s Public Health Ministry (MINSAP, in Spanish) with 15 equipment and five software systems so as to diagnose 21 different diseases, including Hepatitis B and C, HIV, dengue, cystic fibrosis, Chagas disease and leprosy.
mh/pll/acl/joe
